These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15649992)

  • 1. Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan.
    Bell JM; Turnidge JD; Inoue M; Kohno S; Hirakata Y; Ono Y; Jones RN
    J Antimicrob Chemother; 2005 Feb; 55(2):276-8. PubMed ID: 15649992
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2004 May; 49(1):63-5. PubMed ID: 15135503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis).
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Feb; 51(2):139-41. PubMed ID: 15698721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.
    Fritsche TR; Moet GJ; Jones RN
    Clin Microbiol Infect; 2004 Sep; 10(9):857-60. PubMed ID: 15355422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.
    Fonseca-Aten M; Salvatore CM; Mejías A; Ríos AM; Chávez-Bueno S; Katz K; Gómez AM; McCracken GH; Hardy RD
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4128-36. PubMed ID: 16189089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrolactin N, a new peptide deformylase inhibitor produced by Bacillus subtilis.
    Yoo JS; Zheng CJ; Lee S; Kwak JH; Kim WG
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4889-92. PubMed ID: 16809037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide deformylase as an antibacterial target: a critical assessment.
    Leeds JA; Dean CR
    Curr Opin Pharmacol; 2006 Oct; 6(5):445-52. PubMed ID: 16904375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
    Kosowska-Shick K; Credito KL; Pankuch GA; DeWasse B; McGhee P; Appelbaum PC
    Antimicrob Agents Chemother; 2007 Feb; 51(2):770-3. PubMed ID: 17116666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis.
    Cynamon MH; Alvirez-Freites E; Yeo AE
    J Antimicrob Chemother; 2004 Feb; 53(2):403-5. PubMed ID: 14688038
    [No Abstract]   [Full Text] [Related]  

  • 12. Structure-activity relationship analysis and therapeutic potential of peptide deformylase inhibitors.
    Boularot A; Giglione C; Artaud I; Meinnel T
    Curr Opin Investig Drugs; 2004 Aug; 5(8):809-22. PubMed ID: 15600237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor.
    Anderegg TR; Jones RN;
    Diagn Microbiol Infect Dis; 2004 Jan; 48(1):55-7. PubMed ID: 14761722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel potent bicyclic peptide deformylase inhibitors.
    Molteni V; He X; Nabakka J; Yang K; Kreusch A; Gordon P; Bursulaya B; Warner I; Shin T; Biorac T; Ryder NS; Goldberg R; Doughty J; He Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1477-81. PubMed ID: 15006385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slow-binding inhibition of peptide deformylase by cyclic peptidomimetics as revealed by a new spectrophotometric assay.
    Nguyen KT; Hu X; Pei D
    Bioorg Chem; 2004 Jun; 32(3):178-91. PubMed ID: 15110195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecule of the month. LBM-415.
    Drug News Perspect; 2005; 18(1):46. PubMed ID: 15753974
    [No Abstract]   [Full Text] [Related]  

  • 17. The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics.
    Yuan Z; White RJ
    Biochem Pharmacol; 2006 Mar; 71(7):1042-7. PubMed ID: 16289392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDF inhibitors: an emerging class of antibacterial drugs.
    Johnson KW; Lofland D; Moser HE
    Curr Drug Targets Infect Disord; 2005 Mar; 5(1):39-52. PubMed ID: 15777197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards an asymmetric synthesis of the bacterial peptide deformylase (PDF) inhibitor fumimycin.
    Hartmann CE; Gross PJ; Nieger M; Bräse S
    Org Biomol Chem; 2009 Dec; 7(24):5059-62. PubMed ID: 20024097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila.
    Edelstein PH; Hu B; Edelstein MA
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2533-5. PubMed ID: 15917565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.